Pericarditis: Auto-Inflammation in Recurrent Disease

Idiopathic Recurrent Pericarditis Clinical Trial

— PAIReD  

Official title:

An Observational Study to Investigate the Auto-inflammatory Basis of Recurrent Pericarditis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04996108
• Other study ID #: 286959
• Status: Recruiting
• Start date: July 29, 2021
• Est. completion date: June 13, 2024

Study information

• Verified date: July 2021
• Source: King's College London
• Contact: Claire J Peet, BMBCh MRCP
• Phone: 02071886412
• Email: claire.peet[@]kcl.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Pericarditis is swelling of the sac that surrounds the heart, the pericardium, causing chest pain. For most patients, the condition improves with simple anti-inflammatory medications like colchicine and ibuprofen. However, in 20-30% of patients the condition comes back. Diagnosis of recurrent pericarditis is frequently missed or delayed, and many patients require prolonged courses of corticosteroids to control their disease. Together these factors damage the quality of life of patients with recurrent pericarditis. Currently there is limited understanding of why pericarditis comes back in some patients, and how best to treat it when it does.

PAIReD (Pericarditis: Auto-Inflammation in Recurrent Disease) is an observational research study funded by the British Heart Foundation that will investigate the role inflammation plays in recurrent pericarditis. Patients with recurrent pericarditis and other auto-inflammatory diseases will be recruited from the specialist fever clinic at the Royal Free Hospital, where they will be asked to donate blood up to six times over a three year period. Healthy participants will be recruited at the Royal Free Hospital or Guy's Hospital. Relatives of participants with recurrent pericarditis will be recruited at the Royal Free Hospital. They latter two groups will attend one appointment where blood or saliva samples will be taken. A subset of participants will also provide fingerstick blood samples and questionnaires from home, for up to one year.

Clinical data will be collected prospectively and by retrospective case note review. Blood from participants will be analysed to look at how the immune cells of patients with recurrent pericarditis function during the course of their disease, and to look for genetic changes in patients with recurrent pericarditis that might contribute to their condition. Together this knowledge has to potential to help clinicians diagnose and monitor patients with recurrent pericarditis more accurately, and researchers to design more effective treatments.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 119
• Est. completion date: June 13, 2024
• Est. primary completion date: June 13, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

Recurrent pericarditis (RP) cases:

1. Patients with RP, diagnosed by a clinician, meeting the European Society of Cardiology (ESC) diagnostic criteria.

2. Where the aetiology of the RP is defined as idiopathic (i.e. there is no other aetiology identified, such as infective, malignant, post cardiac injury, as part of an autoimmune condition, as part of another known auto-inflammatory disease).

Relatives of RP cases:

First degree relatives of participants meeting the criteria for, and included in the study as, RP cases.

Disease Controls:

Patients with a systemic auto-inflammatory disease, diagnosed by a trained specialist.

Healthy Controls:

Sex, ethnicity and aged matched healthy individuals who do not have a personal history of pericarditis or systemic auto-inflammatory disease.

Exclusion Criteria:

1. Individuals under 12 years of age

2. Adults who are unable to give written informed consent

3. Individuals who have received a blood transfusion within 4 weeks

Related Conditions & MeSH terms

• Idiopathic Recurrent Pericarditis
• Pericarditis

Locations

Country	Name	City	State
United Kingdom	Guy's and St Thomas' NHS Foundation Trust	London
United Kingdom	Royal Free Hospital NHS Foundation Trust	London

Sponsors (3)

Lead Sponsor	Collaborator
King's College London	Guy's and St Thomas' NHS Foundation Trust, Royal Free Hospital NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immune cell phenotype	Exploratory analysis of the proportion, maturity and activation state of different immune cell populations in the peripheral blood, comparing cases and controls and correlated to disease activity in cases	Three years
Primary	Immune cell gene expression	Exploratory analysis of the transcriptome in immune cells in cases compared to controls, and correlated to disease activity in cases.	Three years
Secondary	Genotype	Candidate gene analysis and whole exome sequencing of cases and familial controls.	Three years
Secondary	Clinical phenotype	Characterisation of clinical course of cohort of RP patients, gathering data on disease activity and quality of life prospectively over three years	Three years